相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer
Zaoqu Liu et al.
NATURE COMMUNICATIONS (2022)
SFTPA1 is a potential prognostic biomarker correlated with immune cell infiltration and response to immunotherapy in lung adenocarcinoma
Lu Yuan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)
Cross-Talk of Multiple Types of RNA Modification Regulators Uncovers the Tumor Microenvironment and Immune Infiltrates in Soft Tissue Sarcoma
Lin Qi et al.
FRONTIERS IN IMMUNOLOGY (2022)
Machine learning-based identification of tumor-infiltrating immune cell-associated lncRNAs for improving outcomes and immunotherapy responses in patients with low-grade glioma
Nan Zhang et al.
THERANOSTICS (2022)
LINC00893 inhibits papillary thyroid cancer by suppressing AKT pathway via stabilizing PTEN
Shujing Li et al.
CANCER BIOMARKERS (2021)
Construction autophagy-related prognostic risk signature to facilitate survival prediction, individual treatment and biomarker excavation of epithelial ovarian cancer patients
Hongjun Fei et al.
JOURNAL OF OVARIAN RESEARCH (2021)
Multi-omics consensus ensemble refines the classification of muscle-invasive bladder cancer with stratified prognosis, tumour microenvironment and distinct sensitivity to frontline therapies
Xiaofan Lu et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2021)
Pseudogene HSPA7 is a poor prognostic biomarker in Kidney Renal Clear Cell Carcinoma (KIRC) and correlated with immune infiltrates
Chunjin Ding et al.
CANCER CELL INTERNATIONAL (2021)
Ovarian Cancer Immunotherapy and Personalized Medicine
Susan Morand et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of Ovarian Cancer
Jiao Jiao et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2021)
The N6-Methyladenosine-Modified Pseudogene HSPA7 Correlates With the Tumor Microenvironment and Predicts the Response to Immune Checkpoint Therapy in Glioblastoma
Rongrong Zhao et al.
FRONTIERS IN IMMUNOLOGY (2021)
Overcoming challenges and dogmas to understand the functions of pseudogenes
Seth W. Cheetham et al.
NATURE REVIEWS GENETICS (2020)
TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials
Khalil Choucair et al.
CANCER GENE THERAPY (2020)
Overexpressed PseudogeneHLA-DPB2Promotes Tumor Immune Infiltrates by RegulatingHLA-DPB1and Indicates a Better Prognosis in Breast Cancer
Lijuan Lyu et al.
FRONTIERS IN ONCOLOGY (2020)
The LGMN pseudogene promotes tumor progression by acting as a miR-495-3p sponge in glioblastoma
Keman Liao et al.
CANCER LETTERS (2020)
Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant
Chang Yang et al.
FRONTIERS IN IMMUNOLOGY (2020)
Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy
Tongyan Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Biomarkers in ovarian cancer: To be or not to be
Rebecca Arend et al.
CANCER (2019)
Defining the role of the tumor vasculature in antitumor immunity and immunotherapy
Marco B. Schaaf et al.
CELL DEATH & DISEASE (2018)
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Peng Jiang et al.
NATURE MEDICINE (2018)
Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer
Xiangchun Li et al.
JAMA ONCOLOGY (2018)
Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade
Pornpimol Charoentong et al.
CELL REPORTS (2017)
The NF1 somatic mutational landscape in sporadic human cancers
Charlotte Philpott et al.
HUMAN GENOMICS (2017)
Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors
J. McGee et al.
ANNALS OF ONCOLOGY (2017)
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Panagiotis A. Konstantinopoulos et al.
CANCER DISCOVERY (2015)
Pseudogene in cancer: real functions and promising signature
Lu Xiao-Jie et al.
JOURNAL OF MEDICAL GENETICS (2015)
Loss of Dlg5 expression promotes the migration and invasion of prostate cancer cells via Girdin phosphorylation
L. Tomiyama et al.
ONCOGENE (2015)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy
K. H. Baumann et al.
ANNALS OF ONCOLOGY (2012)
Immunotherapy for Ovarian Cancer: What's Next?
Lana E. Kandalaft et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Subclass Mapping: Identifying Common Subtypes in Independent Disease Data Sets
Yujin Hoshida et al.
PLOS ONE (2007)
Genome-wide midrange transcription profiles reveal expression level relationships in human tissue specification
I Yanai et al.
BIOINFORMATICS (2005)